- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07638189
CBD Knee Osteoarthritis Study
Pilot Study Using Topical Cannabidiol (CBD) to Manage Osteoarthritic Knee Pain
Osteoarthritis of the knee is a common cause of pain in the US. The currently available medicines for knee osteoarthritis sometimes are not effective at relieving the pain or have unacceptable side effects. Thus, alternate pain relieving treatments are needed.
CBD, an active chemical from the hemp derived cannabis sativa plant, has received a lot of attention for its potential pain relieving properties, but there has been limited research to find out if topically applied CBD can decrease pain from knee osteoarthritis. CBD lacks the psychoactive effects seen with marijuana use, because it does not contain THC which is responsible for those effects in marijuana. It is legal to use CBD in the State of Tennessee (site of study).
The CBD Knee Study is sponsored by the University of Tennessee Health Science Center and is a collaborative effort between doctors at UT and Campbell Clinic. In the CBD Knee Study, the investigators are examining whether topically applied CBD dissolved in Castor Oil will relieve knee pain in persons with knee osteoarthritis.
Persons who take part in the study would need to come for study visits, fill out questionnaires about their health and knee pain, and would be asked to use the topical study oil on their knees. Taking part in the CBD Knee Study is voluntary.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Chronic pain is an enormous burden worldwide, impacting more than 30% of the population. Osteoarthritis (OA) is the most common form of joint disfunction and pain, affecting 33 million people in the United States. OA is a prominent cause of pain for older individuals, particularly knee pain. Due to the chronic and progressive nature of OA pain, many patients require long-term analgesic management. Non-steroidal anti-inflammatory drugs (NSAIDs), are commonly used to treat moderate pain from OA, but side effects and numerous potential drug interactions limit use in many individuals. Not surprisingly, opioids became a part of treatment for OA pain in the early 2000s, and have been commonly used for many years even though opioids are not recommend for use by osteoarthritis guideline committees due to their potential risk of misuse, abuse and overdose. With limitations on currently available treatments such as NSAIDs and opioids, the field is now exploring alternative analgesics to manage chronic osteoarthritis pain.
Medical marijuana and cannabis have long been used to treat chronic pain disorders and there is increasing interest to explore cannabinoids as alternate pain therapy. Cannabidiol (CBD), an active cannabinoid from hemp derived cannabis sativa, has garnered attention as a strong pharmaceutical candidate for analgesia. For example, in two recent systematic reviews, CBD was found to be beneficial for treating chronic pain and appeared to improve sleep and Quality of Life (QOL) for persons with chronic pain. CBD lacks the psychoactive effects seen with marijuana use, because it does not contain Δ9- tetrahydrocannabinol (THC) responsible for those effects in marijuana. These properties make CBD a clear candidate for an alternative treatment for chronic pain syndromes such as knee OA.
However, rigorous CBD research is limited in certain chronic pain populations such as persons with OA, but there are some data suggesting benefits. A cross-sectional study, in a large sample of individuals who used oral CBD for arthritis (n=428), showed that 83% reported a reduction in pain following CBD use, and 61% reported a reduction or cessation of other medications, including opioids (18%). There are, however, notable limitations in previous research on CBD for chronic pain that should be acknowledged. Many previous CBD research studies have focused primarily on orally administered CBD often at low doses, which undergoes first-pass metabolism in the liver, reducing bioavailability and potentially diminishing therapeutic effects. Additionally, much of the research relied on the use of over the counter (OTC) CBD products at lower doses, with unverified or untested purity and quality. Thus, additional research on CBD for pain relief is warranted in persons with knee OA. Topical CBD that avoids the first pass metabolism of oral routes has also been shown to reduce chronic pain. In a small randomized clinical trial (n=15) in patients with symptomatic peripheral neuropathy pain, topical CBD Oil use (250 mg / 3 fl. Oz - Higher Dose) resulted in a statistically significant reduction in intense pain, sharp pain and cold/itchy sensations compared with a placebo with no adverse events reported. In another placebo controlled crossover clinical trial in thumb basal joint osteoarthritis, patients had significant reductions in pain after 2 weeks of topical CBD (6.2 mg/ml BID - Lower Dose) administration vs. shea butter (placebo). Another pilot study (n=18) in individuals with hand OA found that topical transdermal CBD gel applied three times daily significantly decreased pain scores (p<0.0001), improved grip strength (p<0.0001), and alleviated stiffness. These findings suggest that topical CBD could represent a promising option for managing chronic localized pain conditions like knee OA. Despite this promising preliminary work, to our knowledge there are no studies using topical CBD at therapeutic doses to treat knee pain in persons with OA to definitively establish efficacy.
There is also a need for a vehicle to deliver the topical CBD dose to the knee area for maximal effect. Castor Oil is an excellent choice. Castor Oil is an odorless vegetable oil made from the seeds of the Castor plant. Castor Oil is already used as a vehicle to assist with delivery of FDA approved topical pain relief medications such as diclofenac sodium (NSAID) to the area of intended use. The main constituent of Castor Oil is ricinoleic acid, which may also have anti-inflammatory and analgesic effects. Thus, Castor Oil is a clear choice as a vehicle to deliver topical CBD to the site of pain in persons with knee OA.
Given healthcare challenges to manage chronic pain, including avoiding opioids because of their addictive potential, investigation of topically applied CBD dissolved in a vehicle such as Castor Oil may provide a promising alternative therapy for the reduction of OA pain of the knee, while having an exceptional safety profile. However, additional research on topical CBD+Castor Oil using rigorous study designs is needed to document efficacy and safety for the treatment of OA pain of the knee.
To address this issue, the investigators will conduct a pilot randomized crossover clinical trial to examine the analgesic efficacy of topical CBD+Castor Oil compared to a topical Castor Oil alone. 30 patients with OA pain of the knee will be randomized. The investigators anticipate 60 patients will sign consent and screen to randomize 30 patients.
SPECIFIC AIMS
Aim 1: Examine medication analgesic efficacy within subjects (n=30) in a balanced crossover design where each participant receives both treatments in randomized order with a 2-week washout period in between. Participants will be randomized to (1) CBD+Castor Oil followed by Castor Oil alone; or 2) Castor Oil alone followed by CBD+Castor Oil. Each oil will be used for a total of 1 month. Hypothesis 1: CBD+Castor Oil will have reduced knee pain scores compare to Castor Oil alone.
Aim 2: Examine changes in knee function, sleep, and knee Quality Of Life (QOL) by medication condition. Hypothesis 2: CBD+Castor Oil will have higher knee function, reduced sleep disturbance scores, and higher QOL than Castor Oil alone.
The investigators hypothesize that with adequate analgesic properties and low safety concerns, topical CBD+Castor Oil may be extremely useful to manage chronic OA knee pain while improving knee function, QOL, and sleep.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní kontakt
- Jméno: Karen Derefinko, PhD
- Telefonní číslo: 901-448-5900
- E-mail: kderefin@uthsc.edu
Studijní záloha kontaktů
- Jméno: William Mihalko, MD, PhD
- Telefonní číslo: 901-448-2666
- E-mail: wmilhalko@uthsc.edu
Studijní místa
-
-
Tennessee
-
Memphis, Tennessee, Spojené státy, 38163
- University of Tennessee Health Science Center
-
Vrchní vyšetřovatel:
- Karen C Johnson, MD, MPH
-
Vrchní vyšetřovatel:
- Karen Derefinko, PhD
-
Dílčí vyšetřovatel:
- William Mihalko, MD, PhD
-
Dílčí vyšetřovatel:
- Phyllis Richey, PhD
-
Dílčí vyšetřovatel:
- Fridtjof Thomas, PhD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Knee OA (grade 2-3 as measured by the Kellgren-Lawrence Classification)
- OA knee pain on the Visual Analog Pain Scale > 4 in either knee
- Receiving treatment at one of the eight Campbell Clinic Orthopaedics locations
Exclusion Criteria:
- Other forms of arthritis such as psoriatic arthritis or rheumatoid arthritis due to different sources of inflammation in these conditions
- Allergies to CBD or Castor Oil
- Current opioid use
- BMI of over 40
- Those who cannot walk without an assistance device (e.g., walker)
- Those who are currently on knee injections (i.e. cortisol or hyaluronic acid gel) for knee pain
- Patients scheduled for a knee replacement in the next 3-6 months
- Active cannabis or CBD use
- Alcohol consumption > 21 alcoholic drinks each week
- Active pregnancy, nursing, or actively planning a pregnancy
- Active chronic liver or renal disease
- Active depression/suicidality
- Medications that interact with CBD in the liver that cannot be discontinued 14. Discretion of the Multiple Principal Investigators for concerns regarding noncompliance with the study intervention.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: CBD+Castol Oil
250 mg CBD dissolved in 1 ml of Castor Oil to be applied topically to the knee BID
|
250 mg of CBD will be dissolved in 1 ml of Castor Oil.
Participants will use 1ml of this solution on each knee BID
|
|
Komparátor placeba: Castor Oil Alone
1 ml of Castor Oil Alone applied topically to the knee as the placebo comparator BID
|
1 ml of Castor oil alone will be applied to each knee BID as the placebo
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Knee Pain
Časové okno: Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
|
The investigators will use ecological momentary assessment to collect knee pain scores and develop pain trajectories. A Visual Analog Scale of Self-Reported Pain will be assessed at study visits and up to once a day via text message using the Wong-Baker visual analogue scale. A score of 0 is no pain and a score of 10 is severe pain. Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two). Knee Pain will be assessed at the Screening Visit as an eligibility criteria and at Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74). The Baseline One Visit will occur 2 weeks after the Screening Visit. Change in knee pain scores on the Visual Analog Scale of Self-Reported Pain will be assessed from the Baseline One Visit to the the Follow-up One Visit and from the Baseline Two Visit to the the Follow-up Two Visit. |
Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Sleep
Časové okno: Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
|
The PROMIS (Patient-Reported Outcomes Information System) Sleep Questionnaire will be used to assess sleep disturbance and sleep related impairment over the past 7 days.
The questionnaire is divided into two distinct short-form assessments: 1) PROMIS Sleep Disturbance and 2) PROMIS Sleep-Related Impairment.
The PROMIS sleep questionnaire utilizes a standardized T-score metric where the general U.S. population average is 50, with a standard deviation of 10.
Higher scores indicate a greater severity of the concept being measured (e.g., more sleep disturbance or more sleep-related impairment).
Below 55 is within normal limits, 55-59.9 is mild, 60-69.9 is moderate, and 70 and above is severe.
Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two).
Sleep will be assessed at the Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74).
|
Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
|
|
Knee Related Quality of Life and Function
Časové okno: Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
|
The Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire will be used to assess five knee dimensions: pain, symptoms, activities of daily living (ADL), sport and recreation function, and knee-related quality of life. Each dimension is scored from 0 to 100, with 0 indicating extreme problems and 100 indicating no problems. Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two). Knee Related Quality of Life and Function as measured by the KOOS questionnaire will be assessed at the Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74). The Baseline One Visit will occur 2 weeks after the Screening Visit. The Follow-up One Visit will occur 1 month after the Baseline One Visit. The Baseline Two Visit will occur 2 weeks after the Follow-up One Visit. The Follow-up Two Visit will occur 1 month after the Baseline Two Visit. |
Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Adherence with Study Medication
Časové okno: Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
|
The investigators will measure adherence with study medication by weighing the study medication bottles at study visits to determine the number of dosage units used from the bottle during medication periods. This weighing method has been used to assess adherence in other topical medication trials. Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two). Bottle weighing to measure adherence with study medication will be assessed at the Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74). The number of dose units used from the Baseline One Visit to the the Follow-up One Visit will be assessed and the number of dose units used from the Baseline Two Visit to the the Follow-up Two Visit will be assessed. |
Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
|
|
Adherence with Study Medication by Self-report
Časové okno: From enrollment at Day 1 to the end of treatment at Day 74
|
The investigators will also assess adherence with study medication by self-report via text message during medication use weeks up to 60 times between the Baseline One Visit (Day 1) and Follow-up Two Visit (Day 74).
The investigators will use a simple question to ask the participant whether the study oil was placed on the Right Knee (Yes/No) and the Left Knee (Yes/No) today.
This measure will be used to encourage compliance with the Study Intervention.
|
From enrollment at Day 1 to the end of treatment at Day 74
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Karen C Johnson, MD, MPH, University of Tennessee
Publikace a užitečné odkazy
Obecné publikace
- Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008 Jan;58(1):26-35. doi: 10.1002/art.23176.
- Kohn MD, Sassoon AA, Fernando ND. Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis. Clin Orthop Relat Res. 2016 Aug;474(8):1886-93. doi: 10.1007/s11999-016-4732-4. Epub 2016 Feb 12. No abstract available.
- Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes. 2003 Nov 3;1:64. doi: 10.1186/1477-7525-1-64.
- Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1-32. doi: 10.1146/annurev.clinpsy.3.022806.091415.
- Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018 Mar 6;319(9):872-882. doi: 10.1001/jama.2018.0899.
- Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, Johnston KL, Pilkonis PA. Development of short forms from the PROMIS sleep disturbance and Sleep-Related Impairment item banks. Behav Sleep Med. 2011 Dec 28;10(1):6-24. doi: 10.1080/15402002.2012.636266.
- Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001 Oct;134(4):845-52. doi: 10.1038/sj.bjp.0704327.
- Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589. doi: 10.1016/j.joca.2019.06.011. Epub 2019 Jul 3.
- Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, Westlund KN. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016 Jul;20(6):936-48. doi: 10.1002/ejp.818. Epub 2015 Oct 30.
- Lynch ME, Ware MA. Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials. J Neuroimmune Pharmacol. 2015 Jun;10(2):293-301. doi: 10.1007/s11481-015-9600-6. Epub 2015 Mar 22.
- Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014 Jul;30(7):557-64. doi: 10.1097/AJP.0000000000000021.
- De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011 Aug;163(7):1479-94. doi: 10.1111/j.1476-5381.2010.01166.x.
- Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3(Suppl 3):S2. doi: 10.1186/ar4174. Epub 2013 Jul 24.
- Deyo RA, Hallvik SE, Hildebran C, Marino M, Dexter E, Irvine JM, O'Kane N, Van Otterloo J, Wright DA, Leichtling G, Millet LM. Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naive Patients: A Statewide Retrospective Cohort Study. J Gen Intern Med. 2017 Jan;32(1):21-27. doi: 10.1007/s11606-016-3810-3. Epub 2016 Aug 2.
- Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021 May 29;397(10289):2082-2097. doi: 10.1016/S0140-6736(21)00393-7.
- Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis. 2018 Feb 1;9(1):143-150. doi: 10.14336/AD.2017.0306. eCollection 2018 Feb.
- Heineman JT, Forster GL, Stephens KL, Cottler PS, Timko MP, DeGeorge BR Jr. A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. J Hand Surg Am. 2022 Jul;47(7):611-620. doi: 10.1016/j.jhsa.2022.03.002. Epub 2022 May 28.
- Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2020;21(5):390-402. doi: 10.2174/1389201020666191202111534.
- Hall N, James B, Bhuiyan MAN, Crane E, Falgout C, Murnane KS. Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain. J Cannabis Res. 2023 Mar 30;5(1):11. doi: 10.1186/s42238-023-00179-8.
- Bawa Z, Lewis D, Gavin PD, Libinaki R, Joubran L, El-Tamimy M, Taylor G, Meltzer R, Bedoya-Perez M, Kevin RC, McGregor IS. An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Sci Rep. 2024 May 23;14(1):11792. doi: 10.1038/s41598-024-62428-x.
- Zehra A, Burns J, Liu CK, Manza P, Wiers CE, Volkow ND, Wang GJ. Cannabis Addiction and the Brain: a Review. J Neuroimmune Pharmacol. 2018 Dec;13(4):438-452. doi: 10.1007/s11481-018-9782-9. Epub 2018 Mar 19.
- Villanueva MRB, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, Dawood SN, Rabih AM, Niaj A, Raman A, Uprety M, Calero M, Khan S. Efficacy, Safety, and Regulation of Cannabidiol on Chronic Pain: A Systematic Review. Cureus. 2022 Jul 16;14(7):e26913. doi: 10.7759/cureus.26913. eCollection 2022 Jul.
- Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004257. doi: 10.1002/14651858.CD004257.pub2.
- Gidal BE, Vandrey R, Wallin C, Callan S, Sutton A, Saurer TB, Triemstra JL. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Front Pharmacol. 2024 Mar 18;15:1335441. doi: 10.3389/fphar.2024.1335441. eCollection 2024.
- Karuppagounder V, Chung J, Abdeen A, Thompson A, Bouboukas A, Pinamont WJ, Yoshioka NK, Sepulveda DE, Raup-Konsavage WM, Graziane NM, Vrana KE, Elbarbary RA, Kamal F. Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis. Cannabis Cannabinoid Res. 2023 Dec;8(6):1030-1044. doi: 10.1089/can.2021.0244. Epub 2022 Aug 22.
- Patel VR, Dumancas GG, Kasi Viswanath LC, Maples R, Subong BJ. Castor Oil: Properties, Uses, and Optimization of Processing Parameters in Commercial Production. Lipid Insights. 2016 Sep 7;9:1-12. doi: 10.4137/LPI.S40233. eCollection 2016.
- Losina E, Song S, Bensen GP, Katz JN. Opioid Use Among Medicare Beneficiaries With Knee Osteoarthritis: Prevalence and Correlates of Chronic Use. Arthritis Care Res (Hoboken). 2023 Apr;75(4):876-884. doi: 10.1002/acr.24844. Epub 2022 Nov 8.
- Chesney E, McGuire P, Freeman TP, Strang J, Englund A. Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products. Ther Adv Psychopharmacol. 2020 Sep 9;10:2045125320954992. doi: 10.1177/2045125320954992. eCollection 2020.
- Ivers N, Dhalla IA, Allan GM. Opioids for osteoarthritis pain: benefits and risks. Can Fam Physician. 2012 Dec;58(12):e708. No abstract available.
- Anand U, Jones B, Korchev Y, Bloom SR, Pacchetti B, Anand P, Sodergren MH. CBD Effects on TRPV1 Signaling Pathways in Cultured DRG Neurons. J Pain Res. 2020 Sep 11;13:2269-2278. doi: 10.2147/JPR.S258433. eCollection 2020.
- Dettori JR. Loss to follow-up. Evid Based Spine Care J. 2011 Feb;2(1):7-10. doi: 10.1055/s-0030-1267080. No abstract available.
- Graziano PA, Bagner DM, Slavec J, Hungerford G, Kent K, Babinski D, Derefinko K, Pasalich D. Feasibility of intensive parent-child interaction therapy (I-PCIT): Results from an open trial. J Psychopathol Behav Assess. 2015 Mar 1;37(1):38-49. doi: 10.1007/s10862-014-9435-0.
- Varadi G, Zhu Z, Crowley HD, Moulin M, Dey R, Lewis ED, Evans M. Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study. Adv Ther. 2023 Jan;40(1):282-293. doi: 10.1007/s12325-022-02345-5. Epub 2022 Oct 29.
- Gouveia BG, Rijo P, Goncalo TS, Reis CP. Good manufacturing practices for medicinal products for human use. J Pharm Bioallied Sci. 2015 Apr-Jun;7(2):87-96. doi: 10.4103/0975-7406.154424.
- Turcotte JJ, Kelly ME, Aja JM, King PJ, MacDonald JH. Risk factors for progression to total knee arthroplasty within two years of presentation for knee osteoarthritis. J Clin Orthop Trauma. 2021 Feb 18;16:257-263. doi: 10.1016/j.jcot.2021.02.008. eCollection 2021 May.
- Derefinko KJ, Hayden A, Sibley MH, Duvall J, Milich R, Lorch EP. A Story Mapping Intervention to Improve Narrative Comprehension Deficits in Adolescents with ADHD. School Ment Health. 2014 Dec;6(4):251-263. doi: 10.1007/s12310-014-9127-7.
- Pramhas S, Thalhammer T, Terner S, Pickelsberger D, Gleiss A, Sator S, Kress HG. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. Lancet Reg Health Eur. 2023 Nov 10;35:100777. doi: 10.1016/j.lanepe.2023.100777. eCollection 2023 Dec.
- Sibley MH, Graziano PA, Kuriyan AB, Coxe S, Pelham WE, Rodriguez L, Sanchez F, Derefinko K, Helseth S, Ward A. Parent-teen behavior therapy + motivational interviewing for adolescents with ADHD. J Consult Clin Psychol. 2016 Aug;84(8):699-712. doi: 10.1037/ccp0000106. Epub 2016 Apr 14.
- Little MA, Pokhrel P, Sussman S, Derefinko KJ, Bursac Z, Rohrbach LA. Factors Associated with the Adoption of Tobacco Cessation Programmes in Schools. J Smok Cessat. 2017 Mar;12(1):55-62. doi: 10.1017/jsc.2015.17. Epub 2016 Feb 2.
- Bailey UL, Derefinko KJ, Milich R, Lorch EP, Metze A. The Effects of Stimulant Medication on Free Recall of Story Events among Children with ADHD. Journal of Psychopathology and Behavioral Assessment. 2011;33(4):409. doi: 10.1007/s10862-011-9249-2.
- Derefinko KJ, Bailey U, Milich R, Lorch EP, Fillmore MT. The effects of stimulant medication on story comprehension in children with Attention Deficit/Hyperactivity Disorder. School Mental Health. 2009;1(4):171-82.
- Sibley MH PW, Derefinko KD, Kuriyan AB, Sanchez F, Graziano PA. A Pilot Trial of Supporting Teens' Academic Needs Daily (STAND): A parent-adolescent collaborative intervention for ADHD. Journal of Psychopathology and Behavioral Assessment. 2013;35(436-449).
- Varadhan R SE, Louis TA, Segal JB, Weiss CO. Review of Guidance Documents for Selected Methods in Patient Centered Outcomes Research: Standards in Addressing Heterogeneity of Treatment Effectiveness in Observational and Experimental Patient Centered Outcomes Research. http://www.pcori.org/assets/Standards-in-Addressing-Heterogeneity-of-Treatment-Effectiveness-in-Observational-and-Experimental-Patient-Centered-Outcomes-Research.pdf: PCORI; 2012. Review of Guidance Documents for Selected Methods in Patient Centered Outcomes Research: Standards in Addressing Heterogeneity of Treatment Effectiveness in Observational and Experimental Patient Centered Outcomes Research. PCORI2012.
- Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, editors. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jan. Available from http://www.ncbi.nlm.nih.gov/books/NBK126190/
- Gosmanova EO, Lu JL, Streja E, Cushman WC, Kalantar-Zadeh K, Kovesdy CP. Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans. Hypertension. 2014 Nov;64(5):951-7. doi: 10.1161/HYPERTENSIONAHA.114.03805. Epub 2014 Aug 4.
- CITI Program. The Collaborative Institutional Training Initiative (CITI Program) at the University of Miami [09/12/2014]. Available from: https://www.citiprogram.org/.
- New Bloom Labs. https://www.newbloomlabs.com/. Accessed 4-30-2025.
- NIDA Drug Supply Program. https://nida.nih.gov/research/research-data-measures-resources/nida-drug-supply-program. Accessed 4-30-2025.
- Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR. Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol. 2004 Mar;56(3):291-7. doi: 10.1211/0022357022791.
- Tennessee CBD Products not considered Controlled Substances. https://www.tn.gov/agriculture/businesses/hemp/hemp-derived-cannabinoids.html. Accessed 4-30-2025
- Tennseess Hemp-derived CBD Policy. https://www.tn.gov/agriculture/businesses/hemp/hemp-derived-cannabinoids.html. Accessed 4-30-2025.
- Naughton MJ, Wiklund I. A critical review of dimension-specific measures of health-related quality of life in cross-cultural research. Qual Life Res. 1993 Dec;2(6):397-432. doi: 10.1007/BF00422216.
- Radloff L. The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Measurement. 1977;1(3):385-401.
- Hess LM, Saboda K, Malone DC, Salasche S, Warneke J, Alberts DS. Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer. Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2579-83. doi: 10.1158/1055-9965.EPI-05-0104.
- Wong DL, Baker CM. Wong-Baker faces pain rating scale. Pain Management Nursing. 2012.
- Nitbani FO, Tjitda PJP, Wogo HE, Detha AIR. Preparation of Ricinoleic Acid from Castor Oil:A Review. J Oleo Sci. 2022;71(6):781-793. doi: 10.5650/jos.ess21226.
- Final report on the safety assessment of Ricinus Communis (Castor) Seed Oil, Hydrogenated Castor Oil, Glyceryl Ricinoleate, Glyceryl Ricinoleate SE, Ricinoleic Acid, Potassium Ricinoleate, Sodium Ricinoleate, Zinc Ricinoleate, Cetyl Ricinoleate, Ethyl Ricinoleate, Glycol Ricinoleate, Isopropyl Ricinoleate, Methyl Ricinoleate, and Octyldodecyl Ricinoleate. Int J Toxicol. 2007;26 Suppl 3:31-77. doi: 10.1080/10915810701663150.
- Hemp Production and the 2018 Farm Bill: Hearing before the Agriculture, Nutrition, and Forestry, Senate(2019).
- Mun CJ, Suk HW, Davis MC, Karoly P, Finan P, Tennen H, Jensen MP. Investigating intraindividual pain variability: methods, applications, issues, and directions. Pain. 2019 Nov;160(11):2415-2429. doi: 10.1097/j.pain.0000000000001626.
- Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Kristensen S. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022 Jun 1;163(6):1206-1214. doi: 10.1097/j.pain.0000000000002466. Epub 2021 Aug 27.
- Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015 Oct;172(20):4790-805. doi: 10.1111/bph.13250. Epub 2015 Oct 13.
- Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009 Apr;60(1):255-66. doi: 10.1016/j.brainresrev.2008.12.003. Epub 2008 Dec 25.
- Marsicano G, Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest. 2006;29(3 Suppl):27-46.
- Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001 Nov;56(11):1059-68. doi: 10.1046/j.1365-2044.2001.02269.x.
- Boyaji S, Merkow J, Elman RNM, Kaye AD, Yong RJ, Urman RD. The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence. Curr Pain Headache Rep. 2020 Jan 24;24(2):4. doi: 10.1007/s11916-020-0835-4.
- Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020 Jan;132(1):56-61. doi: 10.1080/00325481.2019.1685298. Epub 2019 Nov 12.
- Couch DG, Tasker C, Theophilidou E, Lund JN, O'Sullivan SE. Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clin Sci (Lond). 2017 Oct 25;131(21):2611-2626. doi: 10.1042/CS20171288. Print 2017 Nov 1.
- Esposito G, Filippis DD, Cirillo C, Iuvone T, Capoccia E, Scuderi C, Steardo A, Cuomo R, Steardo L. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytother Res. 2013 May;27(5):633-6. doi: 10.1002/ptr.4781. Epub 2012 Jul 20.
- Baron EP. Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been .... Headache. 2015 Jun;55(6):885-916. doi: 10.1111/head.12570. Epub 2015 May 25.
- Charles CV. 2023 AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older People: A Summary of the Updates. Sr Care Pharm. 2023 Sep 1;38(9):352-354. doi: 10.4140/TCP.n.2023.352. No abstract available.
- Romero-Sandoval EA, Fincham JE, Kolano AL, Sharpe BN, Alvarado-Vazquez PA. Cannabis for Chronic Pain: Challenges and Considerations. Pharmacotherapy. 2018 Jun;38(6):651-662. doi: 10.1002/phar.2115. Epub 2018 May 16.
- Mohammed SYM, Leis K, Mercado RE, Castillo MMS, Miranda KJ, Carandang RR. Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review. Pain Manag Nurs. 2024 Apr;25(2):e76-e86. doi: 10.1016/j.pmn.2023.10.002. Epub 2023 Nov 11.
- Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA. 2015 Jun 23-30;313(24):2474-83. doi: 10.1001/jama.2015.6199.
- da Costa BR, Nuesch E, Kasteler R, Husni E, Welch V, Rutjes AW, Juni P. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2014 Sep 17;2014(9):CD003115. doi: 10.1002/14651858.CD003115.pub4.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- STUDY00000389
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Cannabidiol (CBD)
-
National Institute on Drug Abuse (NIDA)Dokončeno
-
Johns Hopkins UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Zatím nenabírámeTouha | Porucha užívání alkoholu (AUD) | Odvykání od návykové látky; DetoxikaceSpojené státy
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)NáborPeriferní neuropatie v důsledku chemoterapie | Metastatický kolorektální karcinom (CRC) | Oxaliplatinou indukovaná periferní neuropatie u pacientů s rakovinouSpojené státy
-
West Virginia UniversityNational Institute on Drug Abuse (NIDA)NáborJízdní výkon | Účinky kanabidioluSpojené státy
-
Colorado State UniversityDokončenoFarmakokinetika | Metabolismus | Funkce jaterSpojené státy
-
Avecho BiotechnologyNábor
-
Regionshospital NordjyllandAalborg University HospitalZatím nenabírámeMetastatický karcinom prostaty odolný proti kastraci (mCRPC)Dánsko
-
Castleton UniversityStaženo
-
University of Northern ColoradoDokončeno
-
Pure GreenDokončenoMuskuloskeletální bolestSpojené státy